Abstract
The third-generation Epidermal Growth Factor Receptor (EGFR) tyrosine kinase inhibitor (TKI) osimertinib is well-tolerated and can improve disease-free survival (DFS) for EGFR mutant stage IB-IIIA completely resected non-small cell lung cancer (NSCLC) patients. However, limited data on osimertinib as neoadjuvant therapy for resectable, EGFR-mutant NSCLC exists. This multicenter, retrospective study aimed to investigate the efficacy and safety of osimertinib as neoadjuvant therapy in resectable patients with stage IA-IIIB NSCLC.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
